Want to join the conversation?
$SUPN said it is in talks with the FDA on sNDA for migraine. The FDA had asked $SUPN to resubmit the Trokendi XR product label with migraine as an indication prior to completing its review. Company will resubmit the revised label before end June. For 2016, $SUPN expects net product sales to be $200-210MM and operating income to be $28-35MM.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.